<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01990911</url>
  </required_header>
  <id_info>
    <org_study_id>RDPAF1</org_study_id>
    <nct_id>NCT01990911</nct_id>
  </id_info>
  <brief_title>Renal Sympathetic Denervation Prevents Atrial Fibrillation in Patients With Hypertensive Heart Disease: a Pilot Study</brief_title>
  <acronym>RDPAF</acronym>
  <official_title>Renal Sympathetic Denervation Restores Autonomic Imbalance and Prevents Atrial Fibrillation in Patients With Hypertensive Heart Disease: a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pace Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Saarland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Pace Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The autonomic nervous system plays an important role in the precipitation of AF in
      structurally-abnormal hearts. Restoration of autonomic imbalance may therefore prevent
      new-onset AF.

      Renal artery denervation (RDN) is a novel percutaneous procedure that uses radio-frequency
      energy to destroy the sympathetic renal nerves. Symplicity 1 and -2 studies have shown that
      RDN effectively reduces blood pressure in up to 80% of treated patients. LVH regression and
      improvement of diastolic dysfunction follow as a consequence of afterload reduction and
      renin-angiotensin-aldosterone system modulation. RDN may thus also reduce intra-atrial
      pressure resulting in less stretch of the pulmonary venous ostia where most ectopic AF-foci
      originate.

      Hypothesis: RDN restores autonomic imbalance in HTHD and lowers intra-atrial pressure by
      reducing afterload. These synergistic mechanisms may prevent new-onset AF.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      One hundred consenting patients meeting all inclusion criteria will undergo an exercise
      stress test, 2D and M-Mode echocardiograms and 24-hour ambulatory blood pressure holter
      monitoring prior to being randomised to receive either renal denervation (RDN) with a
      Symplicity renal denervation catheter plus medical therapy or medical therapy alone. Coronary
      angiography with/without coronary revascularisation will be performed as per the treating
      cardiologist's clinical judgement and a Reveal® holter will be implanted in all patients at
      the end of the procedure.

      Time zero will be defined as starting at three months after the procedure. Follow up visits
      will be scheduled to scan the holter for the primary end point, i.e. high atrial rates
      (AF-surrogate defined as: &quot;episodes of atrial rate &gt;190 beats per minute for more than 6
      minutes&quot;) or new-onset AF. Patients will be followed six monthly for three years.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">November 2016</completion_date>
  <primary_completion_date type="Anticipated">November 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Atrial fibrillation</measure>
    <time_frame>3 years</time_frame>
    <description>Subclinical atrial tachyarrhythmias (episodes of atrial rate &gt;190 beats per minute for more than 6 minutes) or atrial fibrillation recorded by implantable loop recorder (Reveal® holter).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Restoration of autonomic imbalance</measure>
    <time_frame>3 years</time_frame>
    <description>Restoration of autonomic imbalance: lowering resting heart rate, prolonging the PR-interval and improving heart rate recovery after exercise.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Hypertension</condition>
  <condition>Hypertensive Heart Disease</condition>
  <condition>Atrial Fibrillation</condition>
  <condition>Autonomic Imbalance</condition>
  <arm_group>
    <arm_group_label>Renal denervation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Renal denervation: both renal arteries are denervated by applying radio-frequency energy at application points moving in a helical fashion starting in the distal renal artery and moving to the proximal junction with the abdominal aorta.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medical therapy</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>This group will not receive renal sympathetic denervation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Renal denervation</intervention_name>
    <description>In patients randomized to intervention both renal arteries will be treated with radio-frequency energy as per standard Symplicity protocol.In patients randomized to medical-treatment group only, sham renal denervation will be performed by only injecting contrast agent into both renal arteries.</description>
    <arm_group_label>Renal denervation</arm_group_label>
    <other_name>Symplicity catheter renal denervation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Medical therapy</intervention_name>
    <description>Subjects will continue on their standard medical therapy as prescribed by their treating physician</description>
    <arm_group_label>Renal denervation</arm_group_label>
    <arm_group_label>Medical therapy</arm_group_label>
    <other_name>Three or more blood pressure tablets, including a diuretic</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must have an indication for coronary angiography e.g.

          -  Acute coronary syndrome

          -  Positive stress ECG: - Defined as ≥1mm ST segment shift (depression or elevation) in
             ≥2 contiguous leads with/without chest discomfort)

          -  Age ≥55 years

          -  Office blood pressure ≥160/90mmHg in non-diabetics or ≥150/90mmHg in diabetics

          -  Subjects must be on at least 3 anti-hypertensive drugs, including a diuretic agent

          -  Sinus rhythm

          -  Left ventricular hypertrophy defined on echo as:

          -  Estimated LV mass &gt; 255 g or LVMI &gt;131 g/m2 for men

          -  Estimated LV mass &gt;193 g or LVMI &gt;113 g/m2for women

          -  Left atrial diameter ≥45mm on any echocardiographic window

        Exclusion Criteria:

          -  Estimated glomerular filtration rate (eGFR) &lt; 45ml/min/1.73m2

          -  Renal artery anatomy unsuitable for RDN

          -  Substantial stenotic valvular heart disease

          -  Pregnancy or planned pregnancy

          -  Thyrotoxicosis

          -  Patients needing to undergo coronary artery bypass surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul A Brink, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Tygerberg Hospital and Stellenbosch University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Bohm, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital, Saarland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marshall J Heradien, MBChB; M.Med</last_name>
    <phone>0027- (0)82-011-8278</phone>
    <email>marshtan@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michael Böhm, MD, PhD</last_name>
    <phone>+49 (0)6841-16-23372</phone>
    <email>michael.boehm@uniklinikum-saarland.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Pace Clinic</name>
      <address>
        <city>Tygerberg</city>
        <state>Western Cape</state>
        <zip>7505</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marshall J Heradien, MBChB; M.Med</last_name>
      <phone>0027(0)82-011-8278</phone>
      <email>marshtan@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Marshall J Heradien, MBChB; M.Med</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bonke K Khwinani, B.Tec</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Bohm, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Felix Mahfoud, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paul A Brink, MBChB; PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 9, 2013</study_first_submitted>
  <study_first_submitted_qc>November 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2013</study_first_posted>
  <last_update_submitted>April 28, 2015</last_update_submitted>
  <last_update_submitted_qc>April 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Pace Clinic</investigator_affiliation>
    <investigator_full_name>Marshall Jacobus Heradien</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <keyword>hypertension</keyword>
  <keyword>hypertensive heart disease</keyword>
  <keyword>atrial fibrillation</keyword>
  <keyword>autonomic imbalance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

